Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -533.13%-3.53M | -46.13%815K | ||||||||
Net income from continuing operations | -803.49%-17.86M | ---- | ---- | ---- | ---- | -506.44%-1.98M | ---- | ---- | ---- | ---- |
Operating gains losses | 100.92%57K | ---- | ---- | ---- | ---- | ---6.22M | ---- | ---- | ---- | ---- |
Other non cash items | -16.10%7.2M | ---- | ---- | ---- | ---- | 75.22%8.58M | ---- | ---- | ---- | ---- |
Change In working capital | -25.07%-1.82M | ---- | ---- | ---- | ---- | 59.83%-1.46M | ---- | ---- | ---- | ---- |
-Change in receivables | -107.81%-101K | ---- | ---- | ---- | ---- | 138.33%1.29M | ---- | ---- | ---- | ---- |
-Change in inventory | -2,889.36%-1.31M | ---- | ---- | ---- | ---- | 131.76%47K | ---- | ---- | ---- | ---- |
-Change in prepaid assets | -664.07%-1.3M | ---- | ---- | ---- | ---- | 134.68%231K | ---- | ---- | ---- | ---- |
-Change in payables and accrued expense | 4,444.12%2.95M | ---- | ---- | ---- | ---- | -105.62%-68K | ---- | ---- | ---- | ---- |
-Change in other current assets | 38.19%-1.85M | ---- | ---- | ---- | ---- | -216.21%-2.99M | ---- | ---- | ---- | ---- |
-Change in other working capital | -960.00%-215K | ---- | ---- | ---- | ---- | -91.61%25K | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -533.13%-3.53M | -1,718.46%-2.1M | 1,340.77%1.87M | -4,536.26%-4.22M | 447.17%920K | -46.13%815K | 109.92%130K | -71.05%130K | -125.14%-91K | -113.17%-265K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 58.16%-2.52M | -18.00%-6.01M | ||||||||
Net PPE purchase and sale | 73.90%-1.14M | ---- | ---- | ---- | ---- | 14.25%-4.37M | ---- | ---- | ---- | ---- |
Net business purchase and sale | 16.31%-1.38M | ---- | ---- | ---- | ---- | ---1.64M | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 58.16%-2.52M | 2,172.08%5.49M | -385.80%-8.01M | --0 | --0 | -18.00%-6.01M | -176.04%-265K | -649.09%-1.65M | 99.14%-41K | ---4.06M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | -114.12%-1.64M | 11.78%11.58M | ||||||||
Net common stock issuance | --0 | ---- | ---- | ---- | ---- | -6.62%15.12M | ---- | ---- | ---- | ---- |
Net preferred stock issuance | --0 | ---- | ---- | ---- | ---- | --35K | ---- | ---- | ---- | ---- |
Cash dividends paid | 21.69%-1.64M | ---- | ---- | ---- | ---- | 47.75%-2.09M | ---- | ---- | ---- | ---- |
Proceeds from stock option exercised by employees | --0 | ---- | ---- | ---- | ---- | --27K | ---- | ---- | ---- | ---- |
Net other financing activities | ---- | ---- | ---- | ---- | ---- | 17.55%-1.51M | ---- | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | -114.12%-1.64M | 12.61%-478K | 25.80%-417K | 37.14%-391K | -102.46%-350K | 11.78%11.58M | -35.40%-547K | 41.09%-562K | 78.60%-622K | -2.74%14.23M |
Net cash flow | ||||||||||
Beginning cash position | 75.55%14.84M | ---- | ---- | ---- | ---- | 405.32%8.45M | ---- | ---- | ---- | ---- |
Current changes in cash | -220.26%-7.68M | ---- | ---- | ---- | ---- | -5.81%6.39M | ---- | ---- | ---- | ---- |
End cash Position | -51.76%7.16M | ---- | ---- | ---- | ---- | 75.55%14.84M | ---- | ---- | ---- | ---- |
Free cash flow | -531.47%-22.44M | -395.75%-21.01M | 1,340.77%1.87M | -4,536.26%-4.22M | 447.17%920K | 0.78%-3.55M | 33.82%-4.24M | -71.05%130K | -125.14%-91K | -113.17%-265K |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |